Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/ACE inhibitors and ARBs slow proteinuric chronic kidney disease
Renal · ACEARB-RENAL-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Several large, independent randomised trials that compared these drugs against placebo show they slow kidney decline in people with protein in the urine. In type 2 diabetes with kidney disease, two trials found fewer patients reached hard outcomes such as a doubling of creatinine or kidney failure [1][2], and two further trials showed the same for ACE inhibitors in mixed and non-diabetic kidney disease [4][5]. The benefit was strongest in patients with more protein in the urine [4], exactly the group the claim names. The main limits are that a trial in very advanced kidney disease found no clear benefit from staying on the drugs [7], and in one non-diabetic trial the continuous measure of kidney decline was not significantly different even though fewer patients progressed to kidney failure [5]. The panel read the direction as consistent and carried by hard outcomes, held back only by the advanced-stage boundary and the mixed surrogate result.
Placebo-controlled RCTs in type 2 diabetic nephropathy show losartan cut doubling of serum creatinine by 25 percent and end-stage renal disease by 28 percent [1], and irbesartan lowered the primary composite by 20 percent versus placebo independent of blood pressure [2]. In mixed non-diabetic disease, benazepril reduced the risk of doubling creatinine or dialysis by 53 percent, with the greatest effect above 1 g/24h of proteinuria [4]. In non-diabetic non-nephrotic proteinuria, ramipril reduced progression to end-stage renal failure [5]. AASK found ACE inhibition more effective than other classes on the clinical composite in hypertensive kidney disease [3], and a discontinuation cohort found faster eGFR decline after stopping therapy [28]. The contested point: The evidence and the panel divide on scope and stage: the strongest trials [1][2] are confined to type 2 diabetic nephropathy, and in REIN stratum 1 [5] the continuous GFR-slope endpoint was not significantly different (0.26 vs 0.29) while only the hard endpoint moved. STOP-ACEi [7] found no significant eGFR benefit in advanced CKD (eGFR<30), a boundary the claim's unqualified wording overruns.
All 28 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The two largest placebo-controlled RCTs [1][2] are specific to type 2 diabetic nephropathy; generalisation to all proteinuric CKD rests on smaller trials [4][5], so the claim is broader than its strongest evidence.
In [5] REIN stratum 1 the primary GFR-slope endpoint was not significantly different (ramipril 0.26 vs control 0.29); benefit appeared only on ESRF progression, so the surrogate and the hard endpoint partly dissociate.
Where it remains uncertain. The benefit does not extend cleanly across all stages: STOP-ACEi found no significant eGFR difference in advanced CKD [7], and REIN stratum 1's GFR-slope endpoint was not significant even though ESRF progression fell [5].
Aleatory
Acute eGFR change after starting therapy varies widely between patients and complicates slope-based readouts [6].
Epistemic
Only [7] tests eGFR<30 directly and found no significant benefit from continuation, leaving the late-stage case unresolved.
Inferential
In REIN stratum 1 the continuous GFR slope did not move (0.26 vs 0.29) while ESRF progression did [5], and AASK's class advantage appeared only on the clinical composite [3].
The load-bearing papers from a corpus of 28, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
ARB slows progression on hard renal endpoints in proteinuric type 2 diabetic nephropathy.
“The level of proteinuria declined by 35 percent with losartan (P<0.001 for the comparison with placebo).”
Panel auditInternal validity: high · scope of inference: Type 2 diabetic patients with established nephropathy (proteinuria present at baseline).Key limitations: no effect on death · type 2 diabetic nephropathy only
Independent ARB RCT confirms slowed progression, BP-independently.
“Treatment with irbesartan was associated with a risk of the primary composite end point that was 20 percent lower than that in the placebo group (P=0.02)”
Panel auditInternal validity: high · scope of inference: Hypertensive patients with nephropathy due to type 2 diabetes.Key limitations: ESRD reduction not significant (P=0.07) · type 2 diabetic nephropathy only
ACEi superiority on progression in hypertensive CKD.
“Angiotensin-converting enzyme inhibitors appear to be more effective than beta-blockers or dihydropyridine calcium channel blockers in slowing GFR decline.”
Panel auditInternal validity: high · scope of inference: African American adults with hypertensive renal disease (GFR 20-65).Key limitations: hypertensive not defined-proteinuric CKD · no GFR-slope difference between drugs
At 3 years eGFR did not differ significantly between discontinuation and continuation, with no heterogeneity by proteinuria subgroup.
Panel auditInternal validity: high · scope of inference: Advanced progressive CKD (eGFR <30); discontinuation question, not initiation.Key limitations: advanced CKD only · open-label · ESKD trend favouring continuation not significant
4 of 28 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, independent RCT evidence with hard renal outcomes directly in proteinuric populations carries the claim, with stage and surrogate caveats preventing a higher score.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Placebo-controlled benefit in advanced CKD. The only direct advanced-CKD trial [7] showed no significant eGFR benefit, leaving the late-stage case open where the claim is stated without qualification. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised trial of RAS inhibition versus placebo in proteinuric eGFR<30 CKD powered on eGFR slope and ESKD.
Open question: Do ACE inhibitors or ARBs slow progression in proteinuric CKD at eGFR<30, or is there a stage boundary beyond which benefit is lost? Why it is still open: [7] found no significant eGFR difference between continuation and discontinuation in advanced CKD, and no placebo-controlled slope benefit at this stage is in the corpus.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19